用于治疗新生血管性年龄相关性黄斑变性的当前及未来抗血管内皮生长因子药物
Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration.
作者信息
Kaiser Stephanie M, Arepalli Sruthi, Ehlers Justis P
机构信息
Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.
出版信息
J Exp Pharmacol. 2021 Sep 29;13:905-912. doi: 10.2147/JEP.S259298. eCollection 2021.
Abstract
Age-related macular degeneration (AMD) is the most common cause of legal blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (ie, bevacizumab, ranibizumab, aflibercept) provide high-efficacy therapy but can also require frequent dosing. Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended.
摘要
年龄相关性黄斑变性（AMD）是发达国家法定失明的最常见原因。新生血管性（即湿性）AMD目前采用玻璃体腔内治疗。传统治疗方法（即贝伐单抗、雷珠单抗、阿柏西普）提供高效治疗，但也可能需要频繁给药。更新的以及未来的抗血管内皮生长因子（VEGF）疗法旨在通过延长半衰期或端口给药系统（布罗利珠单抗、康柏西普、KSI-301、雷珠单抗）来减少注射频率。本综述概述了当前的抗VEGF治疗方法及其持续时间可能延长的方式。
相似文献
1
Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration.用于治疗新生血管性年龄相关性黄斑变性的当前及未来抗血管内皮生长因子药物
J Exp Pharmacol. 2021 Sep 29;13:905-912. doi: 10.2147/JEP.S259298. eCollection 2021.
2
A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.玻璃体内注射贝伐单抗、雷珠单抗或阿柏西普治疗新生血管性年龄相关性黄斑变性的疗效比较。
Int Ophthalmol. 2017 Oct;37(5):1205-1214. doi: 10.1007/s10792-016-0391-4. Epub 2016 Nov 8.
3
Pipeline therapies for neovascular age related macular degeneration.用于新生血管性年龄相关性黄斑变性的流水线疗法。
Int J Retina Vitreous. 2021 Oct 1;7(1):55. doi: 10.1186/s40942-021-00325-5.
4
Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.血管内皮生长因子抑制剂治疗新生血管性年龄相关性黄斑变性的成本-效用分析。
Am J Ophthalmol. 2020 Oct;218:225-241. doi: 10.1016/j.ajo.2020.05.029. Epub 2020 Jun 19.
5
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.阿柏西普用于既往抗血管内皮生长因子药物治疗无效的新生血管性年龄相关性黄斑变性：一项批判性综述及未来新的可能方法
Angiogenesis. 2015 Oct;18(4):397-432. doi: 10.1007/s10456-015-9483-4. Epub 2015 Sep 7.
6
Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.抗血管内皮生长因子注射治疗新生血管性年龄相关性黄斑变性后的玻璃体内黄斑界面。
Ophthalmology. 2015 Aug;122(8):1569-72. doi: 10.1016/j.ophtha.2015.04.028. Epub 2015 May 30.
7
A safety evaluation of ranibizumab in the treatment of age-related macular degeneration.雷珠单抗治疗年龄相关性黄斑变性的安全性评价。
Expert Opin Drug Saf. 2014 Sep;13(9):1259-70. doi: 10.1517/14740338.2014.939951. Epub 2014 Aug 5.
8
Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.接受阿柏西普转换治疗后 1 年的注射频率与解剖学结局：年龄相关性黄斑变性新生血管患者。
Br J Ophthalmol. 2014 Sep;98(9):1205-7. doi: 10.1136/bjophthalmol-2013-304829. Epub 2014 May 2.
9
[Anti-VEGF therapy resistance in neovascular age-related macular degeneration].[新生血管性年龄相关性黄斑变性中的抗血管内皮生长因子治疗抵抗]
Vestn Oftalmol. 2017;133(4):103-108. doi: 10.17116/oftalma20171334103-108.
10
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.玻璃体内注射阿柏西普、贝伐单抗和雷珠单抗的全身药代动力学和药效学
Retina. 2017 Oct;37(10):1847-1858. doi: 10.1097/IAE.0000000000001493.
引用本文的文献
1
Investigation of novel combination therapy for age-related macular degeneration on ARPE-19 cells.在ARPE-19细胞上对年龄相关性黄斑变性新型联合疗法的研究。
Front Drug Deliv. 2024 Apr 19;4:1337686. doi: 10.3389/fddev.2024.1337686. eCollection 2024.
2
Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review.布罗鲁单抗用于湿性年龄相关性黄斑变性（AMD）和息肉状脉络膜血管病变（PCV）治疗的叙述性综述。
Medicine (Baltimore). 2025 Jun 6;104(23):e42666. doi: 10.1097/MD.0000000000042666.
3
An Engineered Intravitreal Injection Retinal-Pigment-Epithelium-Tropic Adeno-Associated Virus Vector Expressing a Bispecific Antibody Binding VEGF-A and ANG-2 Rescues Neovascular Age-Related Macular Degeneration in Animal Models and Patients.一种表达双特异性抗体结合血管内皮生长因子-A（VEGF-A）和血管生成素-2（ANG-2）的工程化玻璃体内注射视网膜色素上皮靶向腺相关病毒载体可挽救动物模型和患者中的新生血管性年龄相关性黄斑变性。
Research (Wash D C). 2025 May 29;8:0717. doi: 10.34133/research.0717. eCollection 2025.
4
Artemisinin and Its Derivatives: Promising Therapeutic Agents for Age-Related Macular Degeneration.青蒿素及其衍生物：治疗年龄相关性黄斑变性的有前景的治疗药物。
Pharmaceuticals (Basel). 2025 Apr 6;18(4):535. doi: 10.3390/ph18040535.
5
Phacoemulsification surgery in patients with diabetic macular edema: should intravitreal anti-VEGF therapy be performed before or simultaneously with surgery?糖尿病性黄斑水肿患者的超声乳化手术：玻璃体内抗血管内皮生长因子治疗应在手术前还是与手术同时进行？
Int J Ophthalmol. 2025 Apr 18;18(4):637-641. doi: 10.18240/ijo.2025.04.09. eCollection 2025.
6
Allogeneic RPE cell suspension manufactured at scale demonstrating preclinical safety and efficacy led to IND approval.规模化生产的同种异体视网膜色素上皮（RPE）细胞悬液在临床前研究中显示出安全性和有效性，从而获得了研究性新药（IND）批准。
NPJ Regen Med. 2025 Apr 19;10(1):19. doi: 10.1038/s41536-025-00407-0.
7
Preclinical evaluation of NG101, a potential AAV gene therapy for wet age-related macular degeneration.NG101的临床前评估，一种用于湿性年龄相关性黄斑变性的潜在腺相关病毒基因疗法。
Mol Ther Methods Clin Dev. 2024 Nov 5;32(4):101366. doi: 10.1016/j.omtm.2024.101366. eCollection 2024 Dec 12.
8
Anti-VEGF Monotherapy vs Anti-VEGF and Steroid Combination Therapy for Diabetic Macular Edema: A Meta-analysis.抗血管内皮生长因子单药治疗与抗血管内皮生长因子联合类固醇治疗糖尿病性黄斑水肿的Meta分析
J Vitreoretin Dis. 2024 Oct 10:24741264241280597. doi: 10.1177/24741264241280597.
9
Efficacy and safety of intravitreal conbercept and triamcinolone acetonide for wet age-related macular degeneration in China: a meta-analysis.中国腔内康柏西普和曲安奈德治疗湿性年龄相关性黄斑变性的疗效和安全性：一项荟萃分析。
Int Ophthalmol. 2024 Nov 11;44(1):424. doi: 10.1007/s10792-024-03346-9.
10
Age-Related Macular Degeneration (AMD): Pathophysiology, Drug Targeting Approaches, and Recent Developments in Nanotherapeutics.年龄相关性黄斑变性（AMD）：发病机制、药物靶点方法及纳米治疗学的最新进展。
Medicina (Kaunas). 2024 Oct 8;60(10):1647. doi: 10.3390/medicina60101647.
本文引用的文献
1
Association of Early Anatomic Response with Visual Function in Neovascular Age-Related Macular Degeneration.新生血管性年龄相关性黄斑变性早期解剖学反应与视觉功能的关联
Ophthalmology. 2021 Nov;128(11):1657-1660. doi: 10.1016/j.ophtha.2021.05.011. Epub 2021 May 18.
2
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.抗病毒联合治疗在新冠病毒感染有症状患者中的安全性和有效性 - 一项随机对照试验（SEV-COVID 试验）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.
3
Abicipar pegol for neovascular age-related macular degeneration.阿柏西普用于新生血管性年龄相关性黄斑变性。
Expert Opin Biol Ther. 2020 Sep;20(9):999-1008. doi: 10.1080/14712598.2020.1782379. Epub 2020 Jul 3.
4
Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date.雷珠单抗眼内植入给药系统治疗年龄相关性黄斑变性的潜在疗效：迄今证据
Clin Ophthalmol. 2020 May 19;14:1349-1355. doi: 10.2147/OPTH.S194234. eCollection 2020.
5
Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration.阿柏西普：一种用于湿性年龄相关性黄斑变性治疗的在研抗 VEGF 药物。
Expert Opin Investig Drugs. 2020 Jul;29(7):651-658. doi: 10.1080/13543784.2020.1772754. Epub 2020 Jun 1.
6
New Frontiers in Retina: highlights of the 2020 angiogenesis, exudation and degeneration symposium.视网膜新前沿：2020年血管生成、渗出与变性研讨会亮点
Int J Retina Vitreous. 2020 May 22;6:18. doi: 10.1186/s40942-020-00221-4. eCollection 2020.
7
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study.阿柏西普治疗新生血管性年龄相关性黄斑变性的疗效和安全性：III 期随机对照研究 52 周结果。
Ophthalmology. 2020 Oct;127(10):1331-1344. doi: 10.1016/j.ophtha.2020.03.035. Epub 2020 Apr 9.
8
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW.在初治的新生血管性年龄相关性黄斑变性患者中玻璃体内注射阿柏西普给药方案的影响：RAINBOW 研究的 2 年结果。
BMC Ophthalmol. 2020 May 25;20(1):206. doi: 10.1186/s12886-020-01468-z.
9
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.眼内注射布罗鲁单抗后视网膜血管炎和眼内炎症。
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
10
Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.Brolucizumab：通过临床前和临床研究的发展及其对新生血管性年龄相关性黄斑变性治疗的影响。
Ophthalmology. 2020 Jul;127(7):963-976. doi: 10.1016/j.ophtha.2019.12.031. Epub 2020 Jan 17.
Zotero 插件